# Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer

> **NCT02349867** · PHASE1 · COMPLETED · sponsor: **Virginia Commonwealth University** · enrollment: 23 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma
- Stage IA Pancreatic Cancer
- Stage IB Pancreatic Cancer
- Stage IIA Pancreatic Cancer
- Stage IIB Pancreatic Cancer
- Stage III Pancreatic Cancer
- Recurrent Pancreatic Carcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Sorafenib
- **DRUG:** Vorinostat
- **RADIATION:** 3-Dimensional Conformal Radiation Therapy
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **OTHER:** RosetteSep
- **OTHER:** DEPfff

## Key facts

- **NCT ID:** NCT02349867
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-29
- **Primary completion:** 2020-05-13
- **Final completion:** 2022-05-13
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02349867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02349867, "Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02349867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*